International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

NCT05593770 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
28
Enrollment
OTHER
Sponsor class

Stopped Following a meeting of the DSMB on 20th September 2023, the recommendation was made to the sponsor on 26th September 2023 that the Fostamatinib arm of the trial ceases enrolment and study medication is discontinued immediately.

Conditions

Interventions

Sponsor

NEAT ID Foundation